

Certificate of Analysis for NR-46045

Staphylococcus aureus, Strain HT 20020351

Catalog No. NR-46045

Product Description:

Staphylococcus aureus (S. aureus), strain HT 20020351 was isolated in 2002 from a male inpatient in France. S. aureus, strain HT 20020351 was deposited to BEI Resources as part of the NARSA collection. NR-46045 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70039297 Manufacturing Date: 18SEP2020

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-positive cocci	Gram-positive cocci
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Motility (wet mount)	Report results	Non-motile
Hemolysis	Report results	β-hemolytic
Biochemical characterization		
Catalase	Positive	Positive
Coagulase	Report results	Positive
VITEK® MS (MALDI-TOF)	S. aureus	S. aureus (99.9%)
Antibiotic Susceptibility Profile ^{1,2}		
Cefinase™ Paper Disc		1
Beta-lactamase	Report results	Positive
Etest [®] antibiotic test strips 1 day at 35°C in an aerobic atmosphere on Mueller Hinton agar		
Chloramphenicol	Report results	Sensitive (4 µg/mL)
Teicoplanin	Sensitive	Sensitive (1.5 µg/mL)
Quinupristin/dalfopristin	Sensitive	Sensitive (0.5 µg/mL)
VITEK® AST-GP78 card		
Cefoxitin screen	Report results	Negative
Benzylpenicillin	Report results	Resistant (≥ 0.5 µg/mL)
Oxacillin	Sensitive	Sensitive (≤ 0.5 μg/mL)
Ceftaroline	Report results	Sensitive (0.25 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 0.5 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (≤ 0.5 μg/mL)
Levofloxacin	Report results	Sensitive (0.25 µg/mL)
Moxifloxacin	Report results	Sensitive (≤ 0.25 µg/mL)
Clindamycin (inducible resistance)	Report results	Negative
Erythromycin	Intermediate	Sensitive (≤ 0.25 μg/mL) ³
Clindamycin	Sensitive	Sensitive (0.25 µg/mL)
Linezolid	Sensitive	Sensitive (2 µg/mL)
Daptomycin	Report results	Sensitive (≤ 0.5 μg/mL)
Vancomycin	Sensitive	Sensitive (1 µg/mL)
Minocycline	Report results	Sensitive (≤ 0.5 μg/mL)
Tetracycline	Report results	Sensitive (≤ 1 μg/mL)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898




Certificate of Analysis for NR-46045

TEST	SPECIFICATIONS	RESULTS
Tigecycline	Report results	Sensitive (≤ 0.12 μg/mL)
Nitrofurantoin	Report results	Sensitive (32 µg/mL)
Rifampicin	Report results	Sensitive (≤ 0.5 μg/mL)
Trimethoprim/sulfamethoxazole	Sensitive	Sensitive (≤ 10 μg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1430 base pairs)	≥ 99% sequence identity to S. aureus type strain (GenBank: L37597)	100% sequence identity to S. aureus type strain (GenBank: L37597)
Purity (post-freeze) 7 days at 37°C in an aerobic atmosphere with 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

07 SEP 2021

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898

²MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

³S. aureus, strain HT 20020351 was deposited as intermediate to erythromycin, but showed a MIC of ≤ 0.25 μg per mL (interpreted as sensitive) for erythromycin during QC testing. Testing was performed in duplicate.